ASTRO 2022 | Rationale of Phase III PCS5 trial of hypofractionated radiotherapy for prostate cancer

Tamim Niazi, MD, McGill University, Montreal, Quebec, Canada, discusses the randomized Phase III PCS5 trial (NCT01444820) of high-risk prostate cancer patients randomized to receive hypofractionated radiotherapy or standard fractionated radiotherapy. The aim of the study was to determine the feasibility and tolerability of dose escalation radiotherapy for high-risk prostate cancer patients. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.